Author

S. Scheaffer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1

Frequent Co-Authors

A. Addetia· 1 shared A. C. Boon· 1 shared A. Ceschi· 1 shared A. Franzetti-Pellanda· 1 shared A. Joshi· 1 shared A. Rajesh· 1 shared B. Guarino· 1 shared B. Whitener· 1 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Addetia

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain

B. Ying, C.-Y. Liang, P. Desai, S. Scheaffer, S. Elbashir, D. K. Edwards, L. B. Thackray, M. S. Diamond

This study shows that boosting mice with mRNA vaccines in the ipsilateral or contralateral arm leads to equivalent immune responses and protection against SARS-CoV-2 Omicron.

bioRxiv · Apr 5, 2024Microbiology

NVX-CoV2373 ancestral and NVX-CoV2540 BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters

T. L. Bricker, A. Joshi, N. Soudani, S. Scheaffer, N. Patel, M. G. Xabier, G. Smith, M. Diamond, A. C. Boon

This study evaluates the efficacy of NVX-CoV2373 and NVX-CoV2540 nanoparticle vaccines against the Omicron BA.5 variant in Syrian hamsters, showing reduced viral infection and better protection compared to mRNA vaccines.

bioRxiv · Aug 7, 2023Microbiology

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

bioRxiv · Jan 17, 2023 · PreprintImmunology